Combination of Regorafenib and Nivolumab in Unresectable Hepatocellular Carcinoma
Status:
Recruiting
Trial end date:
2023-05-30
Target enrollment:
Participant gender:
Summary
Regorafenib and nivolumab are proven effective agents for the management of unresectable
hepatocellular carcinoma patients. As preclinical studies have suggested potential synergism
between antiangiogenic agents and immune checkpoint inhibitors, regorafenib and nivolumab may
have synergism in terms of efficacy. Herein, this study investigates the combination of
regorafenib and nivolumab as first-line therapy in patients with unresectable hepatocellular
carcinoma.